GlassScriptPhysician profile
Nickie D Stewart
NPI 1346725090
$1,882.59
in general payments reported to CMS, 2019-2025
24 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $509 · 2022: $472 · 2023: $222 · 2024: $106 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $518.50 | 2021-2023 | Leqvio |
| E.R. Squibb & Sons, L.L.C. | $185.30 | 2021-2022 | |
| Pfizer INC. | $152.09 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.63 | 2021-2025 | Airsupra |
| Harmony Biosciences LLC | $117.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $116.48 | 2021-2022 | |
| Abbvie INC. | $104.99 | 2024-2025 | |
| Lilly USA, LLC | $69.97 | 2025 | Mounjaro, Zepbound, Jardiance |
| Acella Pharmaceuticals, LLC | $53.31 | 2024-2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.80 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $45.04 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.83 | 2025 | Caplyta |
| Novo Nordisk INC | $36.64 | 2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $35.52 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $29.73 | 2021-2025 | Otezla, Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.14 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $25.62 | 2025 | Rexulti |
| Lundbeck LLC | $25.36 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $24.43 | 2021 | |
| Verona Pharma, INC. | $23.81 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $23.68 | 2024 | |
| Corcept Therapeutics | $22.61 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $20.85 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickie Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.